FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2162213420> ?p ?o ?g. }

• W2162213420 endingPage "88" @default.
• W2162213420 startingPage "88" @default.
• W2162213420 abstract "Familial breast cancer was first recognized in the Roman medical literature of 100 AD [1]. The first documentation of familial clustering of breast cancer in modern times was published by Broca, who reported 10 cases of breast cancer in 4 generations of his wife's family [2]. In the middle of the nineteen nineties it was proven at the molecular level that a substantial number of breast and ovarian cancers has hereditary monogenic aetiology [3,4]. Evaluation of frequency of pedigree-clinical signs characteristic for strong aggregations of breast/ovarian cancers among consecutive cases of cancers of these organs as well as analyses of cancer incidence in monozygotic twins indicate that about 30% of breast and ovarian cancers develop because of a strong genetic predisposition [5]. In other breast/ovarian cancers the significance of genetic factors was underestimated. However, recently it has been possible to show the characteristic constitutional background influencing development of cancer also in patients sporadic neoplasms. Therefore now scientists think that in almost all patients cancer a certain genetic background should be detectable, although influencing cancer risk to a various degree. Genetic abnormalities strongly related to cancer are called high risk changes (genes) and abnormalities influencing cancer development to a lower degree are called moderate risk changes (genes). Most frequently strong genetic predisposition to breast/ovarian cancers are related to mutations in the BRCA1 and BRCA2 genes and most often it appears as syndromes of hereditary breast cancer -site-specific (HBC-ss), hereditary breast-ovarian cancer (HBOC) and hereditary ovarian cancer (HOC).In family members of families HBC-ss syndrome only breast cancers but not ovarian cancers are observed. In HBOC syndrome families both breast and ovarian cancers are diagnosed, and in HOC syndrome only ovarian but not breast cancers are detected. Operational clinical-pedigree criteria which we use in order to diagnose definitively or with high probability the discussed syndromes are summarized in Table ​Table1.1. In the vast majority of cancer cases related to moderate risk genes family history is negative. HBC-ss, HBOC and HOC syndromes are clinically and molecularly heterogeneous. Mutations in the BRCA1 and BRCA2 genes are the most frequent cause of these syndromes.Table 1Pedigree-clinical diagnostic criteria of HBC-ss, HBOC and HOC syndromes [6]BRCA1 syndromeIn this syndrome women carry a germline mutation in the BRCA1 gene. Carriers of a BRCA1 mutation have approximately 50-80% lifetime risk of breast cancer and 40% risk of ovarian cancer [7]. We estimate that these risks are 66% for breast cancer and 44% for ovarian cancer in the Polish population (Table ​(Table2).2). Both risks appear to be dependent on the type and localization of the mutation [8-10]. Our findings suggest that the risk of breast cancer in women 5382insC is two times higher than in women 4153delA.Table 2Risk of breast and ovarian cancer in BRCA1 mutation carriers in Poland [8]Incomplete penetrance of BRCA1 suggests that other factors, genetic and non-genetic modifiers, are important in carcinogenesis in the mutation carriers. The risk of ovarian cancer is modified by VNTR locus for HRAS 1 and is increased 2-fold in BRCA1 carriers harbouring one or two rare alleles of HRAS 1 [11]. We reported that the 135G>C variant in the RAD51 gene is strongly protective (OR = 0.5) against both ovarian and breast cancer [12,13].Carriers of a BRCA1 mutation are also at about 10% lifetime risk of fallopian tube and peritoneal cancers [14]. These data about the frequency of ovarian cancer in BRCA1 carriers appear to reflect the combined frequency of ovarian, fallopian tube and peritoneal cancers, because these tumours were diagnosed as ovarian cancers in the past, and because they share similar morphology and cause elevated levels of the marker CA 125.The risk of cancer at other sites may be increased in carriers of a BRCA1 mutation as well, but the evidence is controversial and needs further studies.Breast and ovarian cancer in BRCA1 carriers have particular clinical characteristics. The mean age at onset of breast cancer is about 42-45 years [15,16] and of ovarian cancer is about 54 years [17,18]. 18-32% of breast cancers are bilateral [19,20]. These are rapidly growing tumours: >90% of cases have G3 grade at the time of diagnosis and almost all ovarian cancers in women a BRCA1 mutation are diagnosed in FIGO stage III°/IV°. Medullary, atypical medullary, ducal and oestrogen receptor negative (ER) breast tumours are common in BRCA1 carriers. BRCA1 mutation-positive tumours constitute about 10-15% of all ER-breast cancers [21-23]. Most carriers of a BRCA1 mutation report a positive family history of breast or ovarian cancer (Figure ​(Figure1).1). However, 45% of BRCA1 carriers report a negative family history, mainly because of paternal inheritance and incomplete penetrance (Figure ​(Figure3)3) [20].Figure 1Family HOC syndrome and diagnosed constitutional 4153delA BRCA1 gene mutation.Figure 3Patient ovarian cancer and detected 5382insC BRCA1 mutation from family negative family history." @default.
• W2162213420 created "2016-06-24" @default.
• W2162213420 creator A5003294074 @default.
• W2162213420 creator A5003899536 @default.
• W2162213420 creator A5026014942 @default.
• W2162213420 creator A5026033317 @default.
• W2162213420 creator A5045766478 @default.
• W2162213420 creator A5049419485 @default.
• W2162213420 creator A5055931810 @default.
• W2162213420 creator A5065070297 @default.
• W2162213420 creator A5073620493 @default.
• W2162213420 creator A5090925673 @default.
• W2162213420 date "2008-01-01" @default.
• W2162213420 modified "2023-10-10" @default.
• W2162213420 title "Hereditary breast and ovarian cancer" @default.
• W2162213420 cites W135922588 @default.
• W2162213420 cites W1603626531 @default.
• W2162213420 cites W1776948253 @default.
• W2162213420 cites W1824130241 @default.
• W2162213420 cites W1922400285 @default.
• W2162213420 cites W1961928411 @default.
• W2162213420 cites W1968264169 @default.
• W2162213420 cites W1978585547 @default.
• W2162213420 cites W1979368669 @default.
• W2162213420 cites W1985783262 @default.
• W2162213420 cites W1991555835 @default.
• W2162213420 cites W1995258999 @default.
• W2162213420 cites W1996457137 @default.
• W2162213420 cites W2000765979 @default.
• W2162213420 cites W2001172895 @default.
• W2162213420 cites W2005542290 @default.
• W2162213420 cites W2006033910 @default.
• W2162213420 cites W2007023752 @default.
• W2162213420 cites W2009074196 @default.
• W2162213420 cites W2015688351 @default.
• W2162213420 cites W2022183953 @default.
• W2162213420 cites W2025460005 @default.
• W2162213420 cites W2026727525 @default.
• W2162213420 cites W2031952060 @default.
• W2162213420 cites W2037355114 @default.
• W2162213420 cites W2038793520 @default.
• W2162213420 cites W2043465363 @default.
• W2162213420 cites W2048140101 @default.
• W2162213420 cites W2048303068 @default.
• W2162213420 cites W2048858446 @default.
• W2162213420 cites W2049218484 @default.
• W2162213420 cites W2050126505 @default.
• W2162213420 cites W2051838333 @default.
• W2162213420 cites W2055854757 @default.
• W2162213420 cites W2065447734 @default.
• W2162213420 cites W2067324969 @default.
• W2162213420 cites W2068588019 @default.
• W2162213420 cites W2069457741 @default.
• W2162213420 cites W2071831087 @default.
• W2162213420 cites W2084358426 @default.
• W2162213420 cites W2086691265 @default.
• W2162213420 cites W2089415609 @default.
• W2162213420 cites W2094387387 @default.
• W2162213420 cites W2096169096 @default.
• W2162213420 cites W2103970959 @default.
• W2162213420 cites W2106616822 @default.
• W2162213420 cites W2107837387 @default.
• W2162213420 cites W2109465247 @default.
• W2162213420 cites W2109887368 @default.
• W2162213420 cites W2117679726 @default.
• W2162213420 cites W2119286095 @default.
• W2162213420 cites W2121515794 @default.
• W2162213420 cites W2126839072 @default.
• W2162213420 cites W2129093069 @default.
• W2162213420 cites W2139557430 @default.
• W2162213420 cites W2139892288 @default.
• W2162213420 cites W2143934748 @default.
• W2162213420 cites W2149994587 @default.
• W2162213420 cites W2151308486 @default.
• W2162213420 cites W2153579158 @default.
• W2162213420 cites W2182492050 @default.
• W2162213420 cites W2233865588 @default.
• W2162213420 cites W2280145151 @default.
• W2162213420 cites W2338185498 @default.
• W2162213420 cites W235284659 @default.
• W2162213420 cites W2416722388 @default.
• W2162213420 cites W2417080654 @default.
• W2162213420 cites W2462562632 @default.
• W2162213420 cites W630752951 @default.
• W2162213420 doi "https://doi.org/10.1186/1897-4287-6-2-88" @default.
• W2162213420 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2735784" @default.
• W2162213420 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19804604" @default.
• W2162213420 hasPublicationYear "2008" @default.
• W2162213420 type Work @default.
• W2162213420 sameAs 2162213420 @default.
• W2162213420 citedByCount "7" @default.
• W2162213420 countsByYear W21622134202015 @default.
• W2162213420 countsByYear W21622134202016 @default.
• W2162213420 countsByYear W21622134202017 @default.
• W2162213420 countsByYear W21622134202018 @default.
• W2162213420 countsByYear W21622134202021 @default.
• W2162213420 countsByYear W21622134202023 @default.
• W2162213420 crossrefType "journal-article" @default.

• next